Differentiation-inducing factor-1 (DIF-1) is a chlorinated hexaphenone isolated from Dictyostelium. DIF-1 exhibits antitumor activity in several types of mammalian tumor cells, although the underlying mechanisms remain unknown. On the other hand, recent studies indicate that constitutively activated STAT3 acts as an oncogene and could be a target for antitumor drug. In the present study, we examined the effects of DIF-1 on proliferation of gastric cancer cell lines as well as on its signal transduction pathways, focusing mainly on STAT proteins. DIF-1 inhibited proliferation of gastric cancer cells. Western blot analysis and electrophoretic mobility shift assay showed that DIF-1 inhibited STAT3 activity in an MEK-ERK-dependent manner in gastric cancer cell lines, AGS and MKN28. Moreover, blockade of STAT3 activity by ectopic expression of dominant-negative STAT3 or the Janus kinase inhibitor, tyrphostin AG490, inhibited cell growth of AGS cells. These results suggest that STAT3 activity plays an important role for cell growth in AGS cells, and raises the possibility that inhibition of STAT3 activity is one of the mechanisms responsible for the antitumor effect of DIF-1 in these cells.
Introduction
Differentiation-inducing factor-1(DIF-1) DIF-1 (l-[3,5-dichloro-2,6-dihydroxy-4-methoxyphenyl]-l-hexanone) induces stalk cell formation in the simple eukaryote, Dictyostelium discoideum (Morris et al., 1987) . This molecule inhibits proliferation of several tumor cell lines, at least in part, by promoting differentiation of those cells (Asahi et al., 1995; Kubohara, 1997 ). The precise mechanisms underlying its antiproliferative effects, however, remain unknown.
In mammalian cells, STAT proteins are activated by many cytokines and growth factors, which lead to their sequential dimer formation, followed by nuclear translocation, binding to specific DNA sequences, and regulation of gene expression (Darnell, 1997; Ihle, 1996) . During the past several years, a growing number of reports have indicated that constitutive activation of STATS, especially STAT3, is associated with malignant cell proliferation. Various tumor-derived cell lines as well as samples from human cancer tissue contain constitutively activated STAT3 proteins (Sartor et al., 1997; Yu et al., 1995) and blockade of STAT3 activity suppresses proliferation of these cells (Burke et al., 2001; Garcia et al., 2001; Grandis et al., 1998; Ni et al., 2000; Niu et al., 2001) . Furthermore, transfection of constitutively activated STAT3 molecules in fibroblasts induces cellular transformation and tumor formation in nude mice (Bromberg et al., 1999) . Thus, constitutively activated STAT3 has a role as an oncogene.
Gastric cancer remains one of the most prevalent cancers in the world (Neugut et al., 1996) . Surgical resection is the only effective treatment for gastric cancer, but even patients with curative resection frequently develop systemic or regional relapses. Chemotherapy has also been challenged to improve the curative resection rate or to achieve long-term survival in patients with unresectable gastric cancers. The prognosis, however, is still unsatisfactory, and thus there are many efforts to find agents that can suppress the growth of gastric cancer.
In the present study, we examined the effects of DIF-1 on the proliferation of gastric cancer cell lines as well as on its signal transduction pathways, focusing mainly on STAT proteins.
Results

DIF-1 inhibited proliferation of gastric cancer cell lines
DIF-l inhibits proliferation of several tumor cell lines including hematologic and pancreatic cancers (Asahi et al., 1995; Kubohara et al., 1995; Kubohara, 1997) ; however, its effect on gastric cancer cells has not been reported until now. So, we first tested whether DIF-1 has an antiproliferative effect on gastric cancer cell lines. DIF-1 (20 mm) inhibited cell growth by approximately 40-50% that of the control cells by 72 h in all the gastric cancer cell lines examined (Figure 1a ). This antiproliferative effect of DIF-1 was dose-dependent ( Figure 1b) . A representative time course of AGS and MKN28 cell growth inhibition induced by DIF-1 (20 mm) is shown in Figure 1c . DIF-1 (20 mm) had no observable effect on cell viability in any of the cultures in a trypan blue dye exclusion test (more than 95%, data not shown). Therefore, the antiproliferative effect of DIF-1 was not likely to be because of cytotoxicity. Taken together, these findings indicate that DIF-1 exerts an antiproliferative effect on gastric cancer cell lines by inducing growth arrest.
DIF-1 selectively increased Ser-727, but decreased Tyr-705 phosphorylation of STAT3 in AGS and MKN 28 cells
In Dictyostelium, DIF-1 activates the TTGA-binding transcriptional factor, a homologue of STAT protein, and functions via the reciprocal interaction of a phosphotyrosine residue on one molecule with an SH2 domain on a dimerizing partner like STAT protein (Kawata et al., 1997) . In mammalian cells, STAT proteins have various roles including cell growth and differentiation (Darnell, 1997; Ihle, 1996) . Therefore, we examined whether DIF-1 affects the STAT signaling pathways in gastric cancer cells as in Dictyostelium. Rapid tyrosine phosphorylation is a distinct characteristic of all STAT family members for the primary regulation of their activity (Ihle, 1996) . In contrast, the serine phosphorylation of STATs has varying effects on its function (Chung et al., 1997; Wen et al., 1995; Zhang et al., 1995) . Chung et al. (1997) reported that STAT3 serine phosphorylation inhibits its tyrosine phosphorylation, but the functional significance of serine phosphorylation of STATs is still controversial and will likely vary according to cell type or extracellular stimulus. We examined the effects of DIF-l on tyrosine 
DIF-1 activates both MEK-ERK and PI-3 kinase-Akt pathways in AGS and MKN28 cells
STAT3 has a conserved mitogen-activated protein (MAP) kinase phosphorylation site, -Pro-X-Ser-Pro- (Gonzalez et al., 1991) , which corresponds to Ser-727, that is phophorylated by extracellular signal-regulated kinase (ERK) (Chung et al., 1997) . Several reports indicate that the MEK-ERK pathway inhibits tyrosine phosphorylation of STAT3 (Jain et al., 1998; Sengupta et al., 1998) . To determine whether the mechanism of the increased Ser-727 and decreased Tyr-705 phosphorylation of STAT3 by DIF-1 stimulation involves the MEK-ERK pathway in AGS cells, we examined ERK activation after DIF-1 stimulation using antiphosphospecific ERK antibodies. DIF-1 (20 mm) increased ERK phosphorylation and this increase was abolished by pretreatment with the MEK inhibitor PD98059 in AGS cells ( Figure 3a) . Furthermore, we examined whether DIF-1 activates other known MAP kinases. Jun Nterminal kinase (JNK) and p38 MAP kinase are reported to induce serine phosphorylation of STAT3 (Gollob et al., 1999; Lim and Cao, 1999) or inhibit STAT3 activation (Lim and Cao, 1999) . As shown in Figure 3b , DIF-1 (20 mm) did not activate JNK or p38 MAP kinase in AGS cells, suggesting that neither of these kinases are involved in STAT3 activity after DIF-1 stimulation. DIF-1 also increased Akt phosphorylation, which was abolished by pretreatment with the phosphatidylinositol 3 (PI-3) kinase inhibitor wortmannin as previously reported in other cell lines (Kubohara and Hosaka, 1999) (Figure 3a) . Similar results were observed with MKN28 cells (data not shown). Thus, DIF-1 activates both MEK-ERK and PI-3 kinase-Akt pathways in AGS and MKN28 cells.
ERK activation is required for the increased Ser-727 and decreased Tyr-705 phosphorylation of STAT3 in AGS and MKN28 cells Next, we examined whether ERK activation by DIF-1 was responsible for the increased Ser-727 and decreased Tyr-705 phosphorylation of STAT3 in AGS cells. Inhibition of ERK activation by PD98059 reversed the increased Ser-727 and decreased Tyr-705 phosphorylation of STAT3 in AGS cells (Figure 4a ). In contrast, inhibition of the PI-3 kinase-Akt pathway by wortmannin did not influence the effects of DIF-1 on STAT3 (Figure 4a ). ERK activation as well as the increased Ser-727 and decreased Tyr-705 phosphorylation of STAT3 in response to DIF-1 was observed for at least 6 h after stimulation in AGS cells (Figure 4a ). EMSA also indicated inhibition of STAT3 DNA binding after DIF-1 stimulation, and this inhibition was reversed by PD98059 but not by wortmannin (Figure 4b , lanes 3 and 4). We confirmed the specificity of the protein-DNA interaction by competitor assay using nonspecific or specific cold probe. Specific cold probe, but not 
Blockade of STAT3 activation suppressed growth of AGS cells
In various cancer cell lines, blockade of STAT3 activation suppresses cell growth (Burke et al., 2001; Garcia et al., 2001; Grandis et al., 1998; Ni et al., 2000; Niu et al., 2001) . To determine whether inhibition of STAT3 activation suppresses cell growth of AGS cells, we tested the effect of dominant-negative STAT3 or Janus kinase inhibitor, tyrphostin AG490, which has been shown to block STAT3 activation and suppress cell growth in several tumor cell lines (Burke et al., 2001; Meydan et al., 1996; Ni et al., 2000; Nielsen et al., 1997) .
The dominant-negative STAT3 and AG490 both inhibited STAT3 activation (Figures 5a and b , lower panel) and cell growth (Figures 5a and b, upper panel) of AGS cells. These findings suggest that STAT3 activation has an important role in AGS cell growth.
Discussion
In the present experiments, we examined the effects of DIF-1 on the proliferation of gastric cancer cell lines. We found that DIF-1 suppresses the growth of gastric cancer cell lines. As only cytocidal drugs have been available for the chemotherapy of gastric cancer to date, the application of cytostatic drugs like DIF-1 will provide new therapeutic approaches. We then examined the signal transduction pathway involved in this antiproliferative mechanism. Since DIF-1 activates TTGA-binding transcriptional factor which is homologous to mammalian STAT protein in Dictyostelium (Kawata et al., 1997), we investigated the activation of STAT family proteins in response to DIF-1 in gastric cancer cell lines. Interestingly, in the present experiment, DIF-1 selectively increased Ser-727, but decreased Tyr-705 phosphorylation of STAT3 in AGS and MKN28 cells. Consistent with the decreased tyrosine phosphorylation that is required for nuclear translocation and DNA binding (Darnell, 1997; Ihle, 1996) , Electrophoretic mobility shift assay (EMSA) revealed inhibition of STAT3 DNA binding by DIF-1 stimulation in these cell lines. Since DIF-1 activates a STAT-like protein in Dictyostelium, these results were unexpected. ) were seeded in 100-mm dishes and cultured in growth medium for 48 h followed by feeding with serum-free media for 12 h. Then, cells were stimulated with DIF-1 (20 mm) in the presence or absence of pretreatment with 100 nM wortmannin or 20 mm PD98059 for 30 min. Cell lysates were prepared at the indicated time and subjected to immunoblot analysis with antiphospho-specific ERK or Akt antibodies. The proteins were reprobed with antiERK or Akt antibodies to verify equal amounts of protein. The same experiments were performed three times and the data shown are the representative ones. (b) Cell lysates were prepared as described above and subjected to immunoblot analysis with antiphospho-specific JNK or p38 antibodies. The proteins were reprobed with anti-JNK or p38 antibodies to verify equal amounts of protein. Positive control (pos) was included to confirm the efficiency of antiphospho-specific JNK and p38 antibodies using cell lysates exposed to ultraviolet radiation (right lane). The same experiments were performed twice and the data shown are the representative ones
DIF-1 inhibited STAT3 activity M Kanai et al
Several reports indicate that STAT3 is negatively mediated by the MEK-ERK-dependent pathway (Jain et al., 1998; Sengupta et al., 1998) . Therefore, we examined the involvement of the MEK-ERK pathway in decreased STAT3 activity induced by DIF-1 stimulation. As expected, our present findings indicate that the increased Ser-727 and decreased Tyr-705 phosphorylation of STAT3 by DIF-1 are dependent on the MEK-ERK pathway. DIF-1 also activated the PI-3 kinase-Akt pathway, however, blockade of this pathway by wortmannin did not affect the effects of DIF-1 on STAT3 phosphorylation. In addition, neither wortmannin nor the transfection of dominant-negative Akt vector inhibited the antiproliferative effects of DIF-1 (data not shown). These results suggest that the PI-3 kinase-Akt pathway does not contribute to the antiproliferative effects of DIF-1 in AGS and MKN28 cells, although its role remains to be elucidated.
STAT3 has various roles (Darnell, 1997; Ihle, 1996) . Emerging evidence indicates that the constitutive activation of STAT3 is associated with uncontrolled cell proliferation. A number of tumor-derived cell lines as well as samples from human cancer tissues are reported to contain constitutively activated STAT3 proteins (Grandis et al., 1998; Ni et al., 2000; Yu et al., 1995) and blockade of activated STAT3 suppresses proliferation of these cells (Burke et al., 2001; Garcia et al., 2001; Grandis et al., 1998; Ni et al., 2000; Niu et al., 2001) . In the present study, blockade of STAT3 activation by dominant-negative STAT3 or AG490 suppressed the cell growth of AGS cells, indicating that STAT3 activity plays an important role for cell growth in these cells.
In conclusion, DIF-1 suppresses the cell growth of gastric cancer cell lines. Furthermore, DIF-1 inhibits STAT3 activity by an MEK-ERK-dependent pathway in AGS cells, the growth of which is dependent on STAT3 activity. These findings suggest that inhibition of STAT3 activity is one of the mechanisms responsible for the antiproliferative effects of DIF-1 in AGS cells, although the possibilities of other factors and pathways being involved are not excluded. Supporting our idea, several reports indicate that constitutively activated STAT3 could be a target for antitumor drug discovery (Bromberg et al., 1999; Turkson and Jove, 2000) . This is the first report of an antitumor agent that inhibits STAT3 activity through an MEK-ERK-dependent pathway. Because DIF-1 can activate both MEK-ERK and PI-3 kinase-Akt pathways, it is tempting to speculate that gastric cancer cells have the receptor that reacts with DIF-1 and subsequently activates these signal transduction pathways. The clinical application of DIF-1 for an anticancer agent as well as an identification of the direct target of DIF-1 should be examined in future studies. were seeded in 100-mm dishes and cultured in growth medium for 48 h followed by feeding with serum-free media for 12 h. Cells were then stimulated with DIF-1 (20 mm) in the presence or absence of pretreatment with 100 nM wortmannin or 20 nM PD98059 for 30 min. Cell lysates were prepared at the indicated time and subjected to immunoblot analysis with the indicated antibodies. The same experiments were performed three times and the data shown are the representative ones. (b) AGS cells were treated as described above and nuclear extracts (4 mg) were prepared at the indicated time and analyzed for STAT3 activation by EMSA. Competitor assay was performed using nonspecific or specific cold probes at 10 Â the concentration of the labeled probe (lanes 5 and 6). The same experiments were performed three times and the data shown are the representative ones DIF-1 inhibited STAT3 activity M Kanai et al ERK, antiphospho-specific ERK, anti-Akt, antiphosphospecific Akt, anti-JNK, antiphospho-specific JNK, anti-p38, and antiphospho-specific p-38 antibodies were obtained from Cell Signaling Technology (Beverly, MA, USA).
Materials and methods
Reagents and antibodies
DIF
Cell culture
Human gastric cancer cell lines, MKN28, MKN45, MKN74, and AGS were maintained in DMEM/HamF12 medium containing 10% fetal bovine serum, 100 mg/m streptomycin, and 100 IU/ml penicillin in 5% CO 2 at 371C.
Cell proliferation assay
Cells (0.2 Â 10 3 ) seeded in 96-well plates were cultured in growth medium. After 24 h of inoculation, cells were stimulated with or without DIF-1 (20 mm) for 72 h. The proliferation assay was performed using a disulfonated tetrazolium salt, WST-8 (Dojindo, Tokyo, Japan) (Ishiyama et al., 1997) , following the manufacturer's instructions. The microplate reader was used to measure the absorbance at 450 nm.
Western blotting
Following treatment with or without DIF-1 (20 mm) and other agents, cells were lysed in 20 mm Tris-HCl (pH 7.4) buffer containing 150 mm NaCl, 2 mm EDTA, 1% Nonidet P-40 (NP-40), 50 mm NaF, 1 mm Na 3 VO 4 , 1 mm Na 2 MoO 4 , 10mg/ml aprotinin, and 10 mg/ml leupeptin. Equal amounts of protein extracts were fractionated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to polyvinylidene difluoride membranes. The membranes were incubated with primary antibodies and then with peroxidaseconjugated secondary antibodies. Proteins were detected by the enhanced chemiluminescence (ECL) system (Amersham Pharmacia Biotech, Buckinghamshire, England).
Electrophoretic mobility shift assay (EMSA)
Following treatment with or without DIF-1 (20 mm) and other agents, nuclear extracts were prepared and incubated in binding buffer (10 mm Tris-HCl, 0.5 mm DTT, 0.5 mm EDTA, 4% glycerol, 1 mm MgCl 2 , 50 mm NaCl, 500 ng/ml poly-dldC) at room temperature for 20 min with 32 P-labeled m67 (5 0 -dGATTTCCCGTAAATCAT-3 0 ) as previously described (Vinkemeier et al., 1996) . After incubation, each sample was loaded onto a 5% polyacrylamide gel. The gel was then dried and subjected to autoradiography.
Transfections
The dominant-negative STAT3 (phenylalanine substitution at Tyr-705) vectors were created using the in vitro mutagenesis primer set (Takara Biomedicals, Shiga, Japan) according to the manufacturer's instructions as previously described (Nakajima et al., 1996) . Dominant-negative STAT3 was inserted into the Not I site of the pOPRSVI/MCS vector (Stratagene, La Jolla, CA, USA). The resultant plasmids were confirmed by DNA sequences (ABI PRISM 3700 DNA analyzer). Transfection was performed using lipofectamine according to the manufacturer's recommendation (Gibco BRL, Gaithersburg, MD, USA). Stable transfectants expressing dominant-negative STAT3 and vector alone were under selection with 0.3 mg/ml G418. Several clones from each construct were isolated using a cloning ring and expanded. EMSA was performed to determine the efficiency of the incorporated mutant STAT3 protein functioning in a dominant-negative fashion. 
